FATE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fate Therapeutics Inc (FATE) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows weak financial performance, no positive trading signals, and lacks significant positive catalysts. Additionally, technical indicators and options data do not support a strong bullish case.
The MACD is slightly positive but contracting, RSI is neutral at 49.239, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot level of 1.334 and has shown a regular market decline of -3.65%. The stock has a high probability of further declines in the short term (-4.13% in the next week and -5.3% in the next month).
NULL identified. No recent news or significant insider/hedge fund activity.
Weak financial performance in Q4 2025, including a 26.40% YoY revenue drop, a 37.92% YoY net income decline, and a 38.64% YoY EPS decrease. No recent congress trading data or influential figure activity. Stock trend analysis indicates a high probability of further declines in the short term.
In Q4 2025, revenue dropped to $1,369,000 (-26.40% YoY), net income dropped to -$32,374,000 (-37.92% YoY), and EPS dropped to -$0.27 (-38.64% YoY). Gross margin remained at 100%, unchanged YoY.
No recent analyst ratings or price target changes available.
